REGN4461 - Mibavademab clinical trials

An Open-Label Study of Mibavademab (REGN4461), a Leptin Receptor Agonist, for the Treatment of Monogenic Obesity Due to Biallelic Loss of Function Variants of the LEP Gene

This study is looking at a new medicine called mibavademab for people with a specific type of genetic obesity. It aims to see how well the medicine helps reduce body weight and improve other related health measures over time.